Table 1 Clinical characteristics
M0 (N = 74) | M1 (N = 161) | Total (N = 235) | |
|---|---|---|---|
Age (years), median (IQR) | 77.3 (71.3–81.3) | 74.8 (70.0–80.4) | 75.1 (70.2–80.6) |
BMI (kg/m2), median (IQR) | 28.3 (25.7–30.9) | 27.7 (25.4–30.1) | 27.7 (25.5–30.4) |
Gleason score at diagnosis, n (%) | |||
≤ 7 | 32 (43.9) | 55 (36.4) | 87 (38.8) |
> 7 | 41 (56.2) | 96 (63.6) | 137 (61.2) |
ECOG performance status, n (%) | |||
ECOG 0–1 | 66 (89.2) | 147 (91.9) | 213 (91.0) |
ECOG 2–3 | 8 (10.8) | 13 (8.1) | 21 (9.0) |
Locally advanced and metastatic disease at diagnosis, n (%) | 7 (9.6) | 63 (39.9) | 70 (30.3) |
Extension of the disease at present, n (%) (multiple answers possible) | 17 (24.3) | 161 (100) | 178 (75.7) |
Bone | 0 (0) | 145 (90.1) | 145 (61.7) |
≤ 5 bone metastases | 0 | 70 (48.3) | 70 (29.8) |
> 5 bone metastases | 0 | 75 (51.7) | 75 (31.9) |
Locoregional lymph nodes | 17 (23.0) | 48 (29.8) | 65 (27.7) |
VDistant lymph nodes | 0 (0) | 36 (22.4) | 36 (15.3) |
Visceral | 0 (0) | 6 (3.7) | 6 (2.6) |
Lung | 0 (0) | 2 (33.3) | 2 (33.3) |
Liver | 0 (0) | 2 (33.3) | 2 (33.3) |
Multiple locations | 0 (0) | 2 (33.3) | 2 (33.3) |
Concomitant disease, n (%) (multiple answers possible) | |||
Hypertension | 42 (56.8) | 93 (57.8) | 135 (57.4) |
Diabetes mellitus | 19 (25.7) | 34 (21.1) | 53 (22.6) |
Obesity | 19 (25.7) | 31 (19.3) | 50 (21.3) |
Cardiovascular disease | 17 (23.0) | 32 (19.9) | 49 (20.9) |
Respiratory disorders | 12 (16.2) | 20 (12.4) | 32 (13.6) |
Anaemia | 7 (9.5) | 17 (10.6) | 24 (10.2) |
Depression | 6 (8.1) | 8 (5.0) | 14 (6.0) |
Laboratory parameters, median (IQR) | |||
PSA (ng/ml) | 11.9 (7.1–30.2) | 24.2 (6.6–63.8) | 17.8 (6.8–43.3) |
Testosterone (ng/dl) | 0.3 (0.1–12) | 0.3 (0.1–2.5) | 0.3 (0.1–5.4) |
Hb (g/dl) | 13.9 (13–14.2) | 13.1 (12–14) | 13.4 (12.2–14.2) |
LDH (UI/I) | 209 (181.3–371.5) | 217.5 (173.8–323.5) | 216 (178.3–349.8) |
Alkaline phosphatase (UI/I) | 77.1 (58–104) | 105 (75.8–176.8) | 94 (70–147) |